Welcome to the Bladder Cancer website! Please take a look around at the content of the journal and other features of this community portal, including joining the discussion thread about the latest challenging cases, or taking a look at the Clinical Trials Corner.

Bladder Cancer is classified as the official journal of the Bladder Cancer Advocacy Network (BCAN). Read more about this new partnership to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities via: tiny.cc/BLC-BCAN_PR

This review looks at the rationale investigate the BCG vaccination against COVID-19. Visual illustrates how BCG-induced trained immunity could prevent COVID-19 infections. From: Noval Rivas, et al., Bladder Cancer, Vol.7, Iss.2, pp. 121–131, 2021

Cedars-Sinai Cancer investigators were part of a team that identified a specific type of bladder cancer most likely to resist first-line treatment. Their study could guide clinicians toward more aggressive treatment or more targeted therapies for some patients with specific subtypes of the disease, ultimately saving lives.

This review looks at demystifying the intricate ways in which sex-specific biology contribute to differences in pathogenesis, as well as discussing future research directions. From: Christa Lam, et al., Bladder Cancer, Vol.8, Iss.3, pp. 241–254, 2022